Lung Cancer Clinical Trial 20203239

[LCID Study Number: 20203239]

S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status

The purpose of this study is to investigate Hypofractionated Radiotherapy followed by Atezolizumab Consolidation in Stage II or III NSCLC patients with borderline performance status.

Disease/Condition: Lung Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: cancerclinicaltrials@lahey.org

Primary Contact Phone: 781-744-3421